Goldman Sachs and Morgan Stanley Jointly Price IPO at $20
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
The deal priced at the top end of the $18.00-$20.00 target range. Goldman Sachs and Morgan Stanley are acting as joint book running managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LCLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LCLN
Wall Street analysts forecast LCLN stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.050
Low
Averages
High
Current: 23.050
Low
Averages
High
No data
About LCLN
Lincoln International Inc is an investment banking advisory firm focused on the private capital markets. Its integrated platform allows to deliver comprehensive, sector-focused advisory services to clients across key areas of the economy. Its experienced professionals provide meaningful and differentiated private capital markets expertise across two segments, Investment Banking Advisory and Valuations and Opinions. The Investment Banking segment comprises mergers and acquisition(M&A) advisory, capital advisory, private funds advisory services, and other services. The segment also advises public and private institutions on a broad spectrum of financial transactions, including buy-side and sell side M&A transactions as well as debt, minority equity, and primary/secondary fundraising, among others. Its Valuations and Opinions segment include portfolio valuations, transaction opinions, board advisory, and disputes advisory.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three IPOs and Seven SPACs Priced This Week
- Successful Pricing of Lincoln Financial: Lincoln Financial (LCLN) priced at $421 million, achieving a market cap of $2.2 billion, indicating strong demand in the private capital markets despite geopolitical and private credit concerns affecting peers.
- Direct Listing of AMASS Brands: Beverage company AMASS Brands (AMSS) completed its direct listing on Nasdaq, yet its stock fell 52% from the $8.98 price of its last funding round, reflecting market caution towards its premium beverage platform.
- Conexeu Sciences Surge: Medical device developer Conexeu Sciences (CNXU) completed a direct listing on Nasdaq, with its stock soaring 260% from the $4.00 price of its most recent private placement, showcasing investor enthusiasm for its unique regenerative medical technology.
- SPACs Pricing Overview: Seven SPACs priced this week, with Oceanhawk Acquisition (OHACU) raising $160 million and Aperture AC (APURU) raising $90 million, demonstrating ongoing market interest in blank check companies despite an uncertain overall market environment.
See More
Lincoln International Stock Surges 13% on IPO Debut
- Strong Opening Performance: Lincoln International (LCLN) saw its stock price jump to $22.51 on its IPO debut, representing a nearly 13% increase from the $20 offering price, indicating strong market confidence in its investment banking operations.
- Continued Price Surge: By approximately 1:38 PM ET, LCLN's shares rose an additional 14% to $22.78, reflecting optimistic investor sentiment regarding the company's growth potential, which may encourage further participation from investors.
- Significant Fundraising: The IPO involved the offering of 20.6 million shares, resulting in approximately $412 million in gross proceeds, while selling shareholders offered 445,942 shares, generating about $8.92 million, thereby enhancing the company's financial strength.
- Clear Use of Proceeds: Lincoln International plans to use the IPO proceeds to purchase 20.6 million newly issued common units and to partially redeem units from certain LILP partners, pay fees related to reorganization transactions, and repay outstanding amounts under its term loan, demonstrating a focus on financial stability.
See More
Lincoln International's Strong IPO Performance
- IPO Day Performance: Lincoln International's shares surged 12.6% on their debut at the New York Stock Exchange, valuing the investment bank at approximately $2.3 billion, indicating strong market confidence in its business model.
- Opening Price Exceeds Expectations: The stock opened at $22.51 per share, surpassing the $20 offer price, reflecting positive investor sentiment regarding the company's growth potential.
- Significant Fundraising: Lincoln and its selling stockholders sold 21 million shares at the top marketed range of $20, successfully raising $421 million, which provides substantial capital for future expansion initiatives.
- Market Environment Insight: Investment bank IPOs have been scarce in New York over the past decade, with many boutique advisory firms opting to sell themselves before reaching the necessary scale for public offerings; Lincoln's successful IPO may encourage more peers to consider going public.
See More
Lincoln International Raises $421 Million in IPO
- Significant Fundraising: Lincoln International successfully raised $421 million by offering 21 million shares at $20 each, the upper end of the $18 to $20 range, indicating strong market confidence in its business model.
- Clear Market Positioning: As an independent investment banking advisory firm focused on private capital markets, Lincoln International provides expert consulting to private equity and private credit investors, further solidifying its position in the global investment banking sector.
- Global Business Presence: With over 30 offices across 14 countries in the Americas, Europe, Middle East, and Asia, the company demonstrates extensive market coverage and international operational advantages, enabling it to better serve global clients.
- Support from Major Underwriters: The involvement of Goldman Sachs, Morgan Stanley, BMO Capital Markets, Citizens JMP, and Evercore ISI as joint bookrunners enhances investor confidence in Lincoln International, signaling strong growth potential for the future.
See More
Lincoln International Prices IPO at $20 per Share
- IPO Pricing: Lincoln International has priced its initial public offering at $20.00 per share for 21,049,988 Class A shares, at the high end of the previously announced range, indicating strong market confidence and potentially raising approximately $421 million for the company.
- Underwriter Option: The firm has granted underwriters a 30-day option to purchase an additional 3,157,498 Class A shares at the IPO price, a strategy that not only provides additional funding flexibility but may also enhance demand for its stock in the market.
- Exchange Listing: The shares are expected to begin trading on the NYSE on May 20 under the ticker symbol LCLN, a listing that will further elevate the company's market visibility and brand influence.
- Funding Utilization Outlook: The offering is anticipated to close on May 21, with the raised funds aimed at supporting the company's expansion plans and enhancing its competitiveness in the global investment banking advisory sector, reflecting the company's confidence in future growth.
See More
Lincoln International IPO and Conexeu Direct Listing Scheduled
- Lincoln International IPO: Lincoln International (LCLN) is set to conduct an IPO in the upcoming week, aiming to raise $400 million with a market cap of $2 billion, showcasing its strong position in the private capital markets despite challenges faced by peers due to geopolitical and private credit concerns.
- Revenue Growth Potential: The firm anticipates a 16% CAGR for client revenues from 2015 to pro forma 2025, indicating sustained growth potential in the investment banking advisory sector, even amidst a challenging market environment.
- Conexeu Direct Listing: Medical device developer Conexeu Sciences (CNXU) plans to complete a direct listing on Nasdaq with an expected market cap of $120 million, highlighting its innovative capabilities in regenerative medicine, particularly for soft tissue fillers and wound care applications.
- Technological Innovation Platform: Conexeu's CXU Scaffold platform utilizes a temperature-sensitive collagen-based solution that forms a scaffold rapidly in the body, which is expected to enhance its competitiveness in the medical market, especially in facial aesthetics and wound treatment.
See More
Three IPOs and Seven SPACs Priced This Week
- Successful Pricing of Lincoln Financial: Lincoln Financial (LCLN) priced at $421 million, achieving a market cap of $2.2 billion, indicating strong demand in the private capital markets despite geopolitical and private credit concerns affecting peers.
- Direct Listing of AMASS Brands: Beverage company AMASS Brands (AMSS) completed its direct listing on Nasdaq, yet its stock fell 52% from the $8.98 price of its last funding round, reflecting market caution towards its premium beverage platform.
- Conexeu Sciences Surge: Medical device developer Conexeu Sciences (CNXU) completed a direct listing on Nasdaq, with its stock soaring 260% from the $4.00 price of its most recent private placement, showcasing investor enthusiasm for its unique regenerative medical technology.
- SPACs Pricing Overview: Seven SPACs priced this week, with Oceanhawk Acquisition (OHACU) raising $160 million and Aperture AC (APURU) raising $90 million, demonstrating ongoing market interest in blank check companies despite an uncertain overall market environment.
See More
Lincoln International Stock Surges 13% on IPO Debut
- Strong Opening Performance: Lincoln International (LCLN) saw its stock price jump to $22.51 on its IPO debut, representing a nearly 13% increase from the $20 offering price, indicating strong market confidence in its investment banking operations.
- Continued Price Surge: By approximately 1:38 PM ET, LCLN's shares rose an additional 14% to $22.78, reflecting optimistic investor sentiment regarding the company's growth potential, which may encourage further participation from investors.
- Significant Fundraising: The IPO involved the offering of 20.6 million shares, resulting in approximately $412 million in gross proceeds, while selling shareholders offered 445,942 shares, generating about $8.92 million, thereby enhancing the company's financial strength.
- Clear Use of Proceeds: Lincoln International plans to use the IPO proceeds to purchase 20.6 million newly issued common units and to partially redeem units from certain LILP partners, pay fees related to reorganization transactions, and repay outstanding amounts under its term loan, demonstrating a focus on financial stability.
See More
Lincoln International's Strong IPO Performance
- IPO Day Performance: Lincoln International's shares surged 12.6% on their debut at the New York Stock Exchange, valuing the investment bank at approximately $2.3 billion, indicating strong market confidence in its business model.
- Opening Price Exceeds Expectations: The stock opened at $22.51 per share, surpassing the $20 offer price, reflecting positive investor sentiment regarding the company's growth potential.
- Significant Fundraising: Lincoln and its selling stockholders sold 21 million shares at the top marketed range of $20, successfully raising $421 million, which provides substantial capital for future expansion initiatives.
- Market Environment Insight: Investment bank IPOs have been scarce in New York over the past decade, with many boutique advisory firms opting to sell themselves before reaching the necessary scale for public offerings; Lincoln's successful IPO may encourage more peers to consider going public.
See More
Lincoln International Raises $421 Million in IPO
- Significant Fundraising: Lincoln International successfully raised $421 million by offering 21 million shares at $20 each, the upper end of the $18 to $20 range, indicating strong market confidence in its business model.
- Clear Market Positioning: As an independent investment banking advisory firm focused on private capital markets, Lincoln International provides expert consulting to private equity and private credit investors, further solidifying its position in the global investment banking sector.
- Global Business Presence: With over 30 offices across 14 countries in the Americas, Europe, Middle East, and Asia, the company demonstrates extensive market coverage and international operational advantages, enabling it to better serve global clients.
- Support from Major Underwriters: The involvement of Goldman Sachs, Morgan Stanley, BMO Capital Markets, Citizens JMP, and Evercore ISI as joint bookrunners enhances investor confidence in Lincoln International, signaling strong growth potential for the future.
See More
Lincoln International Prices IPO at $20 per Share
- IPO Pricing: Lincoln International has priced its initial public offering at $20.00 per share for 21,049,988 Class A shares, at the high end of the previously announced range, indicating strong market confidence and potentially raising approximately $421 million for the company.
- Underwriter Option: The firm has granted underwriters a 30-day option to purchase an additional 3,157,498 Class A shares at the IPO price, a strategy that not only provides additional funding flexibility but may also enhance demand for its stock in the market.
- Exchange Listing: The shares are expected to begin trading on the NYSE on May 20 under the ticker symbol LCLN, a listing that will further elevate the company's market visibility and brand influence.
- Funding Utilization Outlook: The offering is anticipated to close on May 21, with the raised funds aimed at supporting the company's expansion plans and enhancing its competitiveness in the global investment banking advisory sector, reflecting the company's confidence in future growth.
See More
Lincoln International IPO and Conexeu Direct Listing Scheduled
- Lincoln International IPO: Lincoln International (LCLN) is set to conduct an IPO in the upcoming week, aiming to raise $400 million with a market cap of $2 billion, showcasing its strong position in the private capital markets despite challenges faced by peers due to geopolitical and private credit concerns.
- Revenue Growth Potential: The firm anticipates a 16% CAGR for client revenues from 2015 to pro forma 2025, indicating sustained growth potential in the investment banking advisory sector, even amidst a challenging market environment.
- Conexeu Direct Listing: Medical device developer Conexeu Sciences (CNXU) plans to complete a direct listing on Nasdaq with an expected market cap of $120 million, highlighting its innovative capabilities in regenerative medicine, particularly for soft tissue fillers and wound care applications.
- Technological Innovation Platform: Conexeu's CXU Scaffold platform utilizes a temperature-sensitive collagen-based solution that forms a scaffold rapidly in the body, which is expected to enhance its competitiveness in the medical market, especially in facial aesthetics and wound treatment.
See More
